Nasdaq apls.

Find the latest Financials data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.Headline. APLS Jan 2025 120.000 put. finance.yahoo.com - November 23 at 9:19 AM. Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.7% After Insider Selling. americanbankingnews.com - November 23 at 1:49 AM. Alec Machiels Sells 1,250 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock. americanbankingnews.com - November 22 at 4:44 AM. WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates ...Bill Oxford/iStock via Getty Images. Apellis Pharmaceuticals (NASDAQ:APLS) and Beam Therapeutics (NASDAQ:BEAM) will collaborate to develop therapies for complement-driven diseases.; The body's ...Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade information. Instantly APLS has showed a red trend with a performance of -2.34% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 50.19 on Tuesday, 11/28/23 increased the stock’s daily price by 6.04%.

Shares of NASDAQ APLS opened at $49.10 on Friday. The stock has a market cap of $5.82 billion, a P/E ratio of -9.35 and a beta of 0.97. The company has a current ratio of 4.29, a quick ratio of 3.76 and a debt-to-equity ratio of 0.40. Apellis Pharmaceuticals has a 12-month low of $19.83 and a 12-month high of $94.75.Aug 22, 2023 · WALTHAM, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on ...

MarketWatch IBD DJIA 35285.12 0.30% S&P 500 4554.22 0.11% U.S. 10 Yr 4/32 Yield 4.426% 0.15% Sign In Apellis Pharmaceuticals Inc. APLS (U.S.: Nasdaq) Overview News Apellis Pharmaceuticals... 9,367,396. 841,461. 11.1323. Back to APLS Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid ...

Find the latest Financials data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com. 3 дня назад ... The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags.Noteworthy Monday Option Activity: BILL, APLS, CVNA. October 09, 2023 — 03:23 pm EDT. Written by BNK Invest for BNK Invest ->. Looking at options trading activity among components of the Russell ...Citi analyst Yigal Nochomovitz maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) on December 1 and set a price target of $70.00. Yigal Nochomovitz’s Buy rating for ...

Apellis Pharmaceuticals (APLS). Common Shares. Sell: $47.51|Buy: $48.04|Change: 1.73 (-3.50%).

Nov 4, 2023 · WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ...

Nov 30, 2023 · For instance, the price of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stock is up an impressive 177% over the last five years. It's also good to see the share price up 19% over the last quarter. WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...9 de set. de 2023 ... Fintel reports that on September 8, 2023, B of A Securities maintained coverage of Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral ...Sep 27, 2023 · Shares of Apellis Pharmaceuticals ( APLS 6.66%) were down more than 9% on Wednesday, after falling as much as 12% earlier in the day. The company's shares fell following a short-seller report on ... Nov 17, 2023 · Apellis Pharmaceuticals Inc (NASDAQ:APLS) showed a performance of 4.00% in past 30-days. Number of shares sold short was 16.23 million shares which calculate 7.13 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $71.19 to the stock, which implies a rise of 32.73% to its current value.

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...APLS Earnings Date and Information. Apellis Pharmaceuticals last released its quarterly earnings data on November 1st, 2023. The reported ($1.17) EPS for the …Apellis Pharmaceuticals Inc (Symbol: APLS) saw options trading volume of 11,658 contracts, representing approximately 1.2 million underlying shares or approximately 61.6% of APLS's average daily ...Apellis Pharmaceuticals Inc (NASDAQ:APLS) showed a performance of 4.00% in past 30-days. Number of shares sold short was 16.23 million shares which calculate 7.13 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $71.19 to the stock, which implies a rise of 32.73% to its current value.Dec 1, 2023 · During the recent session, Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s traded shares were 1.43 million, with the beta value of the company hitting 0.96. At the last check today, the stock’s price was $57.36, reflecting an intraday gain of 6.48% or $3.49. The 52-week high for the APLS share is $ ... The average twelve-month price prediction for Apellis Pharmaceuticals is $66.50 with a high price target of $93.00 and a low price target of $29.00. Learn more on APLS's analyst rating history. Do Wall Street analysts like Apellis Pharmaceuticals more than its competitors?

NEW YORK, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...APLS | Complete Apellis Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has ...Dec 1, 2023 · During the recent session, Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s traded shares were 1.43 million, with the beta value of the company hitting 0.96. At the last check today, the stock’s price was $57.36, reflecting an intraday gain of 6.48% or $3.49. The 52-week high for the APLS share is $ ... Apellis pharmaceuticals, inc. (nasdaq:apls) saw its share price drive 177% higher over five years. Shareholders gained a total return of 0.7% in the last quarter. Apellis pharmaceuticals made a loss in the past year, but has seen revenue growth of 43% per year. The company has a good track record of growing its revenue at a compound rate of 23% ... NEW YORK, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...WALTHAM, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its ...APLS U.S.: Nasdaq Apellis Pharmaceuticals Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 28, 2023 7:01 p.m. EST Delayed quote $ 46.50 -0.66 -1.40% After Hours Volume: 1...That number of contracts represents approximately 5.6 million underlying shares, working out to a sizeable 101.3% of VRT's average daily trading volume over the past month, of 5.5 million shares ...Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Novartis Announces FDA Approval Of Prostat...

Apellis Pharmaceuticals (NASDAQ:APLS) has entered into separate, privately negotiated exchange agreements with certain holders of its 3.500% Convertible Senior Notes due 2026.; Under the terms of ...

NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...

Get the latest Apellis Pharmaceuticals Inc (APLS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2 ...WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has ...Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.WALTHAM, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...9,367,396. 841,461. 11.1323. Back to APLS Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid ...(NASDAQ: APLS) Apellis Pharmaceuticals currently has 118,499,945 outstanding shares. With Apellis Pharmaceuticals stock trading at $61.58 per share, the total ...WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing ...

GA is an advanced form of age-related macular degeneration and a leading cause of blindness that impacts approximately one million AmericansWinkler and his family saw firsthand the impact of vision... -April 17, 2023 at 07:01 am- MarketScreenerNASDAQ: APLS. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Apellis Pharmaceuticals Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. ... NASDAQ: Apellis Pharmaceuticals Inc Performance. USD USD; Diluted EPS (TTM)-5.23 …WALTHAM, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...Instagram:https://instagram. stock price eqttradestation onlinehow does webull make moneyai destroying humanity WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and ...The forecasts range from a low of 29.29 to a high of $99.75. The average price target represents an increase of 53.76% from its latest reported closing price of 43.31. See our leaderboard of ... sl green realty corp.why do financial advisors push annuities Number of Hedge Fund Shareholders: 36. The number of hedge funds long Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has ticked up steadily over each of the past four quarters, more than doubling ... bond and bond auctions Nov 2, 2023 · Apellis Pharmaceuticals, Inc. APLS reported third-quarter 2023 loss of $1.17 per share, which was wider than the Zacks Consensus Estimate of a loss of 84 cents. The company had reported a loss of ... Headline. APLS Jan 2025 120.000 put. finance.yahoo.com - November 23 at 9:19 AM. Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.7% After Insider Selling. americanbankingnews.com - November 23 at 1:49 AM. Alec Machiels Sells 1,250 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock. americanbankingnews.com - …For instance, the price of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stock is up an impressive 177% over the last five years. It's also good to see the share price up 19% over the last quarter.